Meningococcemia screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Meningococcemia}} | {{Meningococcemia}} | ||
{{CMG}} ; {{AE}} {{Ammu}} | |||
==Overview== | |||
Routine [[screening]] is not recommended for meningococcemia. | |||
==Screening== | |||
*Routine antimicrobial susceptibility testing of meningococcal isolates is not currently recommended. | |||
*Surveillance of susceptibility patterns in populations should be conducted in order to monitor trends in [[N. meningitidis]] susceptibility. | |||
*State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to [[ciprofloxacin]] or other agents used for treatment or prophylaxis is detected. | |||
*Passive and active surveillance systems are used to monitor meningococcal [[disease]], which is a reportable [[disease]] in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS). | |||
*The goals of meningococcal surveillance are: | |||
:*To detect outbreaks of meningococcal [[disease]] so that appropriate control measures can be promptly instituted, and | |||
:*To assess changes in the epidemiology of meningococcal [[disease]] over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies. | |||
*Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate [[vaccine]]. | |||
*Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Bacterial diseases]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 18:03, 18 September 2017
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia screening On the Web |
|
American Roentgen Ray Society Images of Meningococcemia screening |
|
Risk calculators and risk factors for Meningococcemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Routine screening is not recommended for meningococcemia.
Screening
- Routine antimicrobial susceptibility testing of meningococcal isolates is not currently recommended.
- Surveillance of susceptibility patterns in populations should be conducted in order to monitor trends in N. meningitidis susceptibility.
- State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to ciprofloxacin or other agents used for treatment or prophylaxis is detected.
- Passive and active surveillance systems are used to monitor meningococcal disease, which is a reportable disease in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS).
- The goals of meningococcal surveillance are:
- To detect outbreaks of meningococcal disease so that appropriate control measures can be promptly instituted, and
- To assess changes in the epidemiology of meningococcal disease over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies.
- Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate vaccine.
- Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.[1]